ReviewJournal of translational medicine2026
Epigenetic modulation of the JAK2-STAT3 signaling pathway in osteoporosis: non-coding RNA networks as therapeutic targets.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- On the correlation of tryptophan and its kynurenine pathway metabolites level in blood, saliva and urine in systemic sclerosis patients.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis, a prevalent metabolic bone disease affects over 200 million people worldwide and is associated with an elevated fracture risk, is characterized by an imbalance between bone resorption and formation. The JAK2-STAT3 signaling pathway serves as a critical regulator of bone remodeling, but its chronic activation contributes to pathological bone metabolism in osteoporosis. Understanding the precise regulation of this pathway is essential for developing novel therapies. MAIN BODY: Our review reveals that specific miRNAs directly target components of the JAK2-STAT3 pathway (e.g. JAK2, STAT3, SOCS) to fine-tune osteoblast and osteoclast activity. This regulatory network is further expanded by lncRNAs and circRNAs, which act as competitive endogenous RNAs (ceRNAs) or "molecular sponges" to sequester miRNAs, thereby indirectly modulating JAK2-STAT3 signaling. This multi-tiered ncRNA network influences key processes such as osteogenic differentiation, inflammatory response and mitochondrial redox homeostasis, ultimately determining bone metabolic balance.
conclusionThe ncRNA network represents a promising therapeutic target for bone-related and metabolic diseases, especially osteoporosis, through its precise control over the JAK2-STAT3 pathway. Targeting these ncRNAs, potentially via engineered exosomes or biomaterial-based delivery systems, offers a novel and different strategy for restoring bone homeostasis, paving the way for future precision medicine in bone metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.